Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis
Ken-ichiro Sasaki, … , Satoshi Shintani, Tsutomu Imaizumi
Ken-ichiro Sasaki, … , Satoshi Shintani, Tsutomu Imaizumi
Published March 1, 2002
Citation Information: J Clin Invest. 2002;109(5):603-611. https://doi.org/10.1172/JCI13055.
View: Text | PDF
Article

Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis

  • Text
  • PDF
Abstract

The role of the renin-angiotensin system (RAS) in angiogenesis is little known. Here, we show that the angiotensin II (ATII) type 1 (AT1) receptor plays an important role in ischemia-induced angiogenesis. Well-developed collateral vessels and angiogenesis were observed in wild-type (WT) mice in response to hindlimb ischemia, whereas these responses were reduced in ATII type 1a receptor knockout (AT1a–/–) mice. Ischemia-induced angiogenesis was also impaired in WT mice treated with the AT1 receptor blocker TCV-116. These effects were not due to reduced systemic blood pressure (SBP), because hydralazine treatment preserved angiogenesis in WT mice although it reduced SBP to a level similar to that of AT1a–/– mice. Infiltration of inflammatory mononuclear cells (MNCs), including macrophages and T lymphocytes, was suppressed in the ischemic tissues of AT1a–/– mice compared with WT mice. Double immunofluorescence staining revealed that infiltrated macrophages and T lymphocytes expressed VEGF, and the expression of VEGF and monocyte chemoattractant protein-1 was also decreased in AT1a–/–. Finally, the impaired angiogenesis in AT1a–/– mice was rescued by intramuscular transplantation of MNCs obtained from WT mice, further indicating the importance of MNC infiltration in ischemia-induced angiogenesis. Thus, the ATII–AT1 receptor pathway promotes early angiogenesis by supporting inflammatory cell infiltration and angiogenic cytokine expression.

Authors

Ken-ichiro Sasaki, Toyoaki Murohara, Hisao Ikeda, Takeshi Sugaya, Toshifumi Shimada, Satoshi Shintani, Tsutomu Imaizumi

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
Effects of hydralazine and ATII receptor blockers on ischemia-induced an...
Effects of hydralazine and ATII receptor blockers on ischemia-induced angiogenesis. No impairment in ischemic/normal hindlimb LDBF ratio was observed in WT mice treated with hydralazine (WT + Hydralazine) (P = NS vs. WT). Administration of the AT1 receptor blocker TCV-116 (5 mg/kg/d) impaired ischemia-induced angiogenesis in WT mice (WT + TCV-116) (P < 0.01 vs. WT), so that the LDBF values were comparable to those observed in AT1a–/– mice. Administration of the AT2 receptor blocker PD123319 (30 mg/kg/d) did not alter ischemia-induced angiogenesis in AT1a–/– mice (AT1a–/– + PD123319) (P = NS vs. AT1a–/–).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts